Introduction
The main urokinase plasminogen activating system (uPAS) be composed of the urokinase plasminogen activator (uPA), its cognate receptor (uPAR), and two main plasminogen activator inhibitors, PAI-1 and PAI-2. uPA converts plasminogen into the serine protease plasmin that play role in several pathophysiological processes including angiogenesis, tumor progression and dissemination (1) . PAI-1 potently inhibits cell migration (2, 3) and apoptosis (4) . However, tumor growth and vascularization were discovered to decrease in PAI-1 knockout mice (5) and increased levels of PAI-1 were demonstrated to predict poorer rather than better clinical outcome in a great variety of cancers including gastric (6) , colorectal (7) , breast (8) , ovarian (9) , and lung cancer (10) . In contrary to these findings, Chen et al observed that both tumor growth and angiogenesis were inhibited in PAI-1 overexpressed prostate carcinoma cells (11) . Eitzman DT et al demonstrated that growth of murine melanoma tumors' metastasis was unaffected by the presence of PAI-1 expression (12). Almholt K et al demonstrated PAI-1 status did not influence tumor growth and vascularization in transgenic mice (13) . Adenovirus-mediated PAI-1 gene expression was discovered to decrease the tumor growth, migration and metastasis in vivo (14) (15) (16) . Thyroid carcinoma cell lines and papillary thyroid carcinoma (PTC) tissues overexpress PAI-1 both mRNA and protein levels (17) . Ito et al demonstrated that most thyroid carcinomas diffusely express plasminogen activator inhibitor type 1 (PAI-1) however no association with prognosis was observed (18) . PAI-I evaluated by ELISA were demonstrated to be higher in the cytosolic fraction of malignant thyroid tumor tissues when compared to benign thyroid tumor tissues (19) . PAI-1 evaluated by ELISA was shown to be higher in paired cytosol samples of malignant thyroid tumors and associated with worse prognosis (20) . However, to our knowledge no studies evaluated serum PAI-1 levels in thyroid cancer. In this study, we aimed to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels in patients with papillary thyroid carcinoma (PTC) as well as its effect in development and size of PTC.
Material and Methods

Study population
54 patients (7 male, 47 female) with papillary thyroid cancer (PTC) and 24 age, sex, and BMI-matched controls (6 male, 18 female) were included in the study. Ethics committee approval and written informed consent of participants were obtained prior to the study. The diagnosis of PTC was confirmed by histopathologic documents. Blood was collected from patients before surgery and from healthy individuals as the normal controls. Subjects with other cancers and autoimmune disorder, hypertension, hepatic or renal dysfunction, diabetes mellitus, or any other inflammatory or medical condition were excluded.
Clinical, biochemical and hormonal measurements
Weight, height, waist circumference (WC), hip circumference (HC) and systolic and diastolic blood pressure (BP) were measured. WC was determined by measuring the narrowest point between the costal margin and iliac crest at the end of a normal expiration. The BMI was calculated as weight (kg)/height (m) 2 . After an 8-12 hour overnight fast, the venipuncture was performed between 8:00 am and 9:00 am and blood samples were collected into plain tubes. Blood samples were centrifuged at 2.500 g for 15 min within 30 min of collection, and serum samples were stored at -80 °C until analysis. Serum levels of glucose, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), creatinine, thyroid stimulating hormone (TSH), free T4 (fT4) were also measured.
Measurement of plasminogen activator inhibitor-1
Measurements of PAI1 (eBioscience, USA) were performed in an ELISA reader EPOCH system (BioTek Instruments, Inc, USA) using the commercially available ELISA kit in accordance with the manufacturers' instructions.
Statistical Analysis
The descriptive values for the data obtained are expressed in mean ± SD, numbers, and percentage frequencies. Kolmogorov-Smirnov test was used to review whether the numerical measurements exhibit a normal distribution and it has been determined that the numerical variables are distributed normally. Student's ttest and Mann-Whitney U-test were used to compare differences between two independent groups with normal and non-normal distributions, respectively. The relationships between individual numerical properties were reviewed by Pearson correlation analysis in the patient and control groups. p ≤ 0.05 was used as the statistical significance level and IBM SPSS 20.0 was processed for the calculations.
Results
Mean age was similar between PTC and control group (42.4 ± 10.1 to 42.5 ± 8.9, p:0.794). Serum PAI-1 levels were lower in patients with PTC when compared to healthy controls (241.34 ± 107.82 to 327.24 ± 138.51, p:0.011) ( Figure 1 
Discussion
PAI-1 is the main physiological inhibitor of plasminogen activation by uPA and tPA. uPA is considered to initiate releasing of proteolytic enzymes in tumors, thus facilitates cancer-cell invasion into the surrounding normal tissue via degradation of basement membranes and extracellular matrix (21) . uPA is causally involved in promoting cancer invasion and metastasis (22). PAI-1 is expected to suppress cancer progression due to its ability to inhibit uPA activity however, PAI-1 were found to independent prognostic factors. There are conflicting results about the effect of PAI-1 on tumor growth and metastasis. High PAI-1 levels predict adverse outcome in multiple cancer types including breast, ovary, cervix, endometrium, stomach, colon, lung, bladder, kidney, brain, and soft-tissue (23, 24) . Regulation of plasmin-mediated proteolysis (25, 26 ) and/or cell migration (27) by PAI-1 is considered to be the reason of PAI-1 induced angiogenesis. In contrary to these findings, PAI-1 overexpression in prostate carcinoma cells inhibits both tumor growth and angiogenesis (11) . Moreover, some studies demonstrated that PAI-1 status did not effect tumor (12, 13) . Administration of pharmacological level of PAI-1 was demonstrated to prevent the angiogenesis, tumor growth, and dissemination (28, 29) . Stefansson et al demonstrated that exogenously added PAI-1 at therapeutic concentrations was a potent inhibitor of angiogenesis (30) In vivo studies demonstrated that adenovirus-mediated PAI-1 gene expression decreased the tumor growth, migration, and metastasis (14-16).
Ulisse S et al compared the expression analysis of uPA, uPAR and PAI-1 in human PTC specimens compared to those of normal matched tissues using quantitative RT-PCR and Western blot. They found that higher expression of uPA, uPAR, and PAI-1, at both mRNA and protein levels, correspond to malignant transformation of the human thyrocyte (17) . The highest cytosolic level of PAI-1 was observed in samples with thyroid cancer compared to benign thyroid diseases (19) . These findings were supported by Horvatic Herceg G et al that reported cytosolic PAI-1 levels were significantly higher in differentiated thyroid tumors compared to normal tissues and patients with higher PAI-1 have a poorer prognosis (31) . Ulisse S et reported that the uPA, uPAR, and PAI-1 mRNA levels were significantly higher in patients with papillary, medullary, follicular and anaplastic thyroid cancer compared with normal matched tissues (32) . Another study reported most thyroid carcinomas diffusely express PAI-1, but no relation with clinicopathological parameters was observed (18) . Altogether, these studies demonstrated increased expression of uPAS components in thyroid cancer and the degree of overexpression positively correlates with prognostic factors including tumor size, lymph node, or distant metastases (1) . It was demonstrated that inhibition of uPA and uPAR reduces proliferation, migration and invasive capacity of thyroid cancer cells (33) . In contrary to these results, we found that PAI-1 concentrations were lower in our patient group.
PAI-1 is an inhibitor of uPA and both uPA and PAI-1 appears to be markers of tumor aggressiveness. This apparent paradox could be due to the multiple and complex pathways in which uPA, uPAR and particularly PAI-1 affects tumor biology (34, 35) . Although inhibition of uPA, uPAR or PAI-1 by several approaches has demonstrated to decrease the growth and metastasis of experimental tumors in animals, this inhibition has not been able to show any effect on human cancers (36) . In light of this information, we still don't know for sure how PAI-1 affect tumor behavior in cancer which might partly explain our on the contrary results in this particular study.
In conclusion, serum PAI-1 levels are demonstrated to be significantly lower in thyroid cancer patients compared to healthy controls. Our findings were not consistent with the results of other studies that evaluate the effect of PAI-1 in thyroid cancer. However, our results might support the concept of PAI-1 is expected to suppress cancer progression due to its ability to inhibit uPA activity.
